/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new pooled efficacy and safety analyses from the.
BALTIMORE — Treatment with once-daily oral fezolinetant was effective for reducing moderate to severe hot flashes associated with menopause in a diverse population, according to findings reported at the ACOG Annual Clinical & Scientific Meeting.
This included those with a greater burden of severe and frequent vasomotor symptoms, Black women, women with an elevated BMI and current
Astellas Pharma s non-hormonal menopause drug granted FDA approval pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Announced on May 12, 2023, the FDA's approval of fezolinetant (Veozah) marks their first approval for an NK3 receptor antagonist for the treatment of vasomotor symptoms of menopause.